Innoviva, Inc. cash flow to debt ratio of 73.20% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Innoviva, Inc.'s free cash flow has decreased 1.06% from $188.42M last year to $186.43M, signaling decreasing performance

Innoviva, Inc.'s debt to equity ratio is 0.22, which means that the company's assets are healthy financed, signaling financial stability.

Innoviva, Inc.'s debt has decreased relative to shareholder equity from 0.65 last year to 0.22 today, signaling strengthened financials

Innoviva, Inc. has a net cash position, so leverage is healthy.

Innoviva, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Innoviva, Inc.'s profit margin has increased (1.14K%) in the last year from 6.52% to 80.56%, signaling increasing performance

Innoviva, Inc.'s short-term assets of $727.51M exceed its short-term liabilities of $49.70M

Innoviva, Inc.'s return on assets of 20.98% is higher than the 5.00% threshold, indicating efficient asset utilization

Innoviva, Inc.'s return on equity of 30.03%, is higher than 15.00%, indicating good performance

Innoviva, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Innoviva, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Innoviva, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Innoviva, Inc. has a free cash flow yield of 12.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Innoviva, Inc.'s yearly earnings has increased 1.06K% since last year from $23.39M to $271.17M, signaling increasing performance

Innoviva, Inc.'s yearly revenue has increased 18.52% since last year from $358.71M to $425.13M, signaling increasing performance

ROIC 8.36% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Innoviva, Inc.'s 3-year revenue CAGR of 8.66% is positive, indicating growing revenue over the past 3 years

Innoviva, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Innoviva, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Innoviva, Inc. is undervalued relative to its fair value price of 28.39 based on Discounted Cash Flow model

Innoviva, Inc. has an earnings yield of 23.53%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Innoviva, Inc. is undervalued relative to its fair value price of 46.15 based on EBITDA multiple model

Innoviva, Inc. has an EV/EBITDA ratio of 3.24x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Innoviva, Inc. is undervalued relative to its fair value price of 33.51 based on Earnings Fair Value model

Innoviva, Inc. has a PEG-ratio under 1 which is considered undervalued

Innoviva, Inc. has a price-to-book ratio of 1.23x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Innoviva, Inc. has a price-to-sales ratio of 3.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue